Abstract
BackgroundThe two evidence-based European guidelines available gave some divergent recommendations on first line therapies of fibromyalgia syndrome (FMS). Both guidelines did not consider risks and feasibility of therapies (1,2).ObjectivesTo update...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
